Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2003
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi, Martin C Mihm, Robert J Soiffer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins, David E Elder, Richard Essner, et al.Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsF Stephen Hodi, Marcus Butler, Darryl A Oble, et al.Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanomaMalcolm S Mitchell, Judith Abrams, John A Thompson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapyGeorge D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.The Lancet. Oncology|April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialJeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.Pageof 4